English
Insider transactions
EDGARImunon, Inc.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-20.
- Open-market purchases (code P)
- 0 transactions, — shares
- Open-market sales (code S)
- 6 transactions, 22,385 shares
- Sum of shares × price per share: 38,153.0213
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–50 of 74
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-06 Filed 2026-11-10 | Dentzer James E Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 13,166 | 0.845 | 11,125.27Derived: shares × price per share. Exact value 11125.270. | 34,197 | Direct (D) | No | F1
| Open filing 0001437749-26-036264 Read from the filing’s XML Dispute this row |
| 2026-11-06 Filed 2026-11-10 | Lindborg Stacy Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 3,804 | 0.845 | 3,214.38Derived: shares × price per share. Exact value 3214.380. | 122,581 | Direct (D) | No | F1
| Open filing 0001437749-26-036259 Read from the filing’s XML Dispute this row |
| 2026-11-06 Filed 2026-11-10 | Braun Donald P Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 11,746 | 0.845 | 9,925.37Derived: shares × price per share. Exact value 9925.370. | 33,643 | Direct (D) | No | F1
| Open filing 0001437749-26-036265 Read from the filing’s XML Dispute this row |
| 2026-11-06 Filed 2026-11-10 | Fritz Frederick J. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 13.166 | 0.845 | 11.12527Derived: shares × price per share. Exact value 11.125270. | 28,242 | Direct (D) | No | F1
| Open filing 0001437749-26-036262 Read from the filing’s XML Dispute this row |
| 2026-11-06 Filed 2026-11-10 | Tardugno Michael H Director · Officer: Executive Chairman of Board | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 9,969 | 0.845 | 8,423.805Derived: shares × price per share. Exact value 8423.805. | 128,511 | Direct (D) | No | F1
| Open filing 0001437749-26-036258 Read from the filing’s XML Dispute this row |
| 2026-11-06 Filed 2026-11-10 | Faller Douglas Vincent Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 1,596 | 0.845 | 1,348.62Derived: shares × price per share. Exact value 1348.620. | 76,356 | Direct (D) | No | — | Open filing 0001437749-26-036261 Read from the filing’s XML Dispute this row |
| 2026-11-06 Filed 2026-11-10 | Pellizzari Christine A Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 13,166 | 0.845 | 11,125.27Derived: shares × price per share. Exact value 11125.270. | 28,665 | Direct (D) | No | F1
| Open filing 0001437749-26-036263 Read from the filing’s XML Dispute this row |
| 2026-10-23 Filed 2026-10-27 | Faller Douglas Vincent Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 26,741 | 1.235 | 33,025.135Derived: shares × price per share. Exact value 33025.135. | 74,760 | Direct (D) | No | — | Open filing 0001437749-26-033644 Read from the filing’s XML Dispute this row |
| 2026-10-23 Filed 2026-10-27 | Faller Douglas Vincent Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 1,092 | 1.235 | 1,348.62Derived: shares × price per share. Exact value 1348.620. | 48,019 | Direct (D) | No | — | Open filing 0001437749-26-033644 Read from the filing’s XML Dispute this row |
| 2026-10-23 Filed 2026-10-27 | Lindborg Stacy Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,603 | 1.235 | 3,214.705Derived: shares × price per share. Exact value 3214.705. | 118,777 | Direct (D) | No | F1
| Open filing 0001437749-26-033647 Read from the filing’s XML Dispute this row |
| 2026-10-23 Filed 2026-10-27 | Tardugno Michael H Director · Officer: Executive Chairman of Board | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 6,821 | 1.235 | 8,423.935Derived: shares × price per share. Exact value 8423.935. | 118,542 | Direct (D) | No | F1
| Open filing 0001437749-26-033649 Read from the filing’s XML Dispute this row |
| 2026-10-09 Filed 2026-10-13 | Tardugno Michael H Director · Officer: Executive Chairman of Board | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 7,800 | 1.08 | 8,424Derived: shares × price per share. Exact value 8424.00. | 111,721 | Direct (D) | No | F1
| Open filing 0001437749-26-032563 Read from the filing’s XML Dispute this row |
| 2026-10-09 Filed 2026-10-13 | Faller Douglas Vincent Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 1,249 | 1.08 | 1,348.92Derived: shares × price per share. Exact value 1348.92. | 46,927 | Direct (D) | No | F1
| Open filing 0001437749-26-032560 Read from the filing’s XML Dispute this row |
| 2026-10-09 Filed 2026-10-13 | Lindborg Stacy Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,977 | 1.08 | 3,215.16Derived: shares × price per share. Exact value 3215.16. | 116,174 | Direct (D) | No | F1
| Open filing 0001437749-26-032562 Read from the filing’s XML Dispute this row |
| 2026-09-25 Filed 2026-09-28 | Tardugno Michael H Director · Officer: Executive Chairman of Board | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 7,169 | 1.41 | 10,108.29Derived: shares × price per share. Exact value 10108.29. | 103,921 | Direct (D) | No | F1
| Open filing 0001437749-26-031363 Read from the filing’s XML Dispute this row |
| 2026-09-25 Filed 2026-09-28 | Faller Douglas Vincent Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 4,390 | 1.41 | 6,189.9Derived: shares × price per share. Exact value 6189.90. | 45,678 | Direct (D) | No | F1
| Open filing 0001437749-26-031360 Read from the filing’s XML Dispute this row |
| 2026-09-25 Filed 2026-09-28 | Lindborg Stacy Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 6,697 | 1.41 | 9,442.77Derived: shares × price per share. Exact value 9442.77. | 113,197 | Direct (D) | No | F1
| Open filing 0001437749-26-031362 Read from the filing’s XML Dispute this row |
| 2026-09-11 Filed 2026-09-15 | Lindborg Stacy Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 5,504 | 1.47 | 8,090.88Derived: shares × price per share. Exact value 8090.88. | 105,580 | Direct (D) | No | F1
| Open filing 0001437749-26-030414 Read from the filing’s XML Dispute this row |
| 2026-09-11 Filed 2026-09-15 | Tardugno Michael H Director · Officer: Executive Chairman of Board | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 5,824 | 1.47 | 8,561.28Derived: shares × price per share. Exact value 8561.28. | 95,699 | Direct (D) | No | F1
| Open filing 0001437749-26-030415 Read from the filing’s XML Dispute this row |
| 2026-09-11 Filed 2026-09-15 | Faller Douglas Vincent Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 4,211 | 1.47 | 6,190.17Derived: shares × price per share. Exact value 6190.17. | 41,288 | Direct (D) | No | F1
| Open filing 0001437749-26-030413 Read from the filing’s XML Dispute this row |
| 2026-08-31 Filed 2026-09-01 | Eylward Susan Officer: General Counsel and Corp Sec | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 2,525 | 1.5643 | 3,949.8575Derived: shares × price per share. Exact value 3949.8575. | 2,896 | Direct (D) | No | F2
| Open filing 0001437749-26-029405 Read from the filing’s XML Dispute this row |
| 2026-08-28 Filed 2026-09-01 | Lindborg Stacy Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 6,822 | 1.60 | 10,915.2Derived: shares × price per share. Exact value 10915.20. | 100,076 | Direct (D) | No | F1
| Open filing 0001437749-26-029408 Read from the filing’s XML Dispute this row |
| 2026-08-28 Filed 2026-09-01 | Eylward Susan Officer: General Counsel and Corp Sec | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,525 | 1.60 | 4,040Derived: shares × price per share. Exact value 4040.00. | 5,421 | Direct (D) | No | F1
| Open filing 0001437749-26-029405 Read from the filing’s XML Dispute this row |
| 2026-08-28 Filed 2026-09-01 | Faller Douglas Vincent Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 3,626 | 1.60 | 5,801.6Derived: shares × price per share. Exact value 5801.60. | 37,077 | Direct (D) | No | F1
| Open filing 0001437749-26-029407 Read from the filing’s XML Dispute this row |
| 2026-08-28 Filed 2026-09-01 | Tardugno Michael H Director · Officer: Executive Chairman of Board | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 7,371 | 1.60 | 11,793.6Derived: shares × price per share. Exact value 11793.60. | 89,875 | Direct (D) | No | F1
| Open filing 0001437749-26-029409 Read from the filing’s XML Dispute this row |
| 2026-08-17 Filed 2026-08-17 | Eylward Susan Officer: General Counsel and Corp Sec | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 2,449 | 1.6303 | 3,992.6047Derived: shares × price per share. Exact value 3992.6047. | 2,896 | Direct (D) | No | F2
| Open filing 0001437749-26-028184 Read from the filing’s XML Dispute this row |
| 2026-08-14 Filed 2026-08-17 | Faller Douglas Vincent Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 3,516 | 1.65 | 5,801.4Derived: shares × price per share. Exact value 5801.40. | 33,451 | Direct (D) | No | F1
| Open filing 0001437749-26-028186 Read from the filing’s XML Dispute this row |
| 2026-08-14 Filed 2026-08-17 | Tardugno Michael H Director · Officer: Executive Chairman of Board | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 7,147 | 1.65 | 11,792.55Derived: shares × price per share. Exact value 11792.55. | 82,504 | Direct (D) | No | F1
| Open filing 0001437749-26-028185 Read from the filing’s XML Dispute this row |
| 2026-08-14 Filed 2026-08-17 | Lindborg Stacy Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 6,615 | 1.65 | 10,914.75Derived: shares × price per share. Exact value 10914.75. | 93,254 | Direct (D) | No | F1
| Open filing 0001437749-26-028187 Read from the filing’s XML Dispute this row |
| 2026-08-14 Filed 2026-08-17 | Eylward Susan Officer: General Counsel and Corp Sec | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,449 | 1.65 | 4,040.85Derived: shares × price per share. Exact value 4040.85. | 5,345 | Direct (D) | No | F1
| Open filing 0001437749-26-028184 Read from the filing’s XML Dispute this row |
| 2026-08-03 Filed 2026-08-04 | Eylward Susan Officer: General Counsel and Corp Sec | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 2,541 | 1.5651 | 3,976.9191Derived: shares × price per share. Exact value 3976.9191. | 2,896 | Direct (D) | No | F2
| Open filing 0001437749-26-025661 Read from the filing’s XML Dispute this row |
| 2026-07-31 Filed 2026-08-04 | Faller Douglas Vincent Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 3,649 | 1.59 | 5,801.91Derived: shares × price per share. Exact value 5801.91. | 29,935 | Direct (D) | No | F1
| Open filing 0001437749-26-025658 Read from the filing’s XML Dispute this row |
| 2026-07-31 Filed 2026-08-04 | Pellizzari Christine A Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 6,934 | 1.59 | 11,025.06Derived: shares × price per share. Exact value 11025.06. | 15,076 | Direct (D) | No | F1
| Open filing 0001437749-26-025671 Read from the filing’s XML Dispute this row |
| 2026-07-31 Filed 2026-08-04 | Tardugno Michael H Director · Officer: Executive Chairman of Board | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 6,358 | 1.59 | 10,109.22Derived: shares × price per share. Exact value 10109.22. | 75,357 | Direct (D) | No | F1
| Open filing 0001437749-26-025660 Read from the filing’s XML Dispute this row |
| 2026-07-31 Filed 2026-08-04 | Fritz Frederick J. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 6,934 | 1.59 | 11,025.06Derived: shares × price per share. Exact value 11025.06. | 21,031 | Direct (D) | No | F1
| Open filing 0001437749-26-025665 Read from the filing’s XML Dispute this row |
| 2026-07-31 Filed 2026-08-04 | Eylward Susan Officer: General Counsel and Corp Sec | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,541 | 1.59 | 4,040.19Derived: shares × price per share. Exact value 4040.19. | 5,437 | Direct (D) | No | F1
| Open filing 0001437749-26-025661 Read from the filing’s XML Dispute this row |
| 2026-07-31 Filed 2026-08-04 | Braun Donald P Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 6,180 | 1.59 | 9,826.2Derived: shares × price per share. Exact value 9826.20. | 15,499 | Direct (D) | No | F1
| Open filing 0001437749-26-025663 Read from the filing’s XML Dispute this row |
| 2026-07-31 Filed 2026-08-04 | Dentzer James E Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 6,934 | 1.59 | 11,025.06Derived: shares × price per share. Exact value 11025.06. | 21,897 | Direct (D) | No | F1
| Open filing 0001437749-26-025667 Read from the filing’s XML Dispute this row |
| 2026-07-31 Filed 2026-08-04 | Lindborg Stacy Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 5,010 | 1.59 | 7,965.9Derived: shares × price per share. Exact value 7965.90. | 86,639 | Direct (D) | No | F1
| Open filing 0001437749-26-025655 Read from the filing’s XML Dispute this row |
| 2026-07-20 Filed 2026-07-21 | Eylward Susan Officer: General Counsel and Corp Sec | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 2,150 | 1.7816 | 3,830.44Derived: shares × price per share. Exact value 3830.4400. | 2,896 | Direct (D) | No | F2
| Open filing 0001437749-26-023948 Read from the filing’s XML Dispute this row |
| 2026-07-17 Filed 2026-07-21 | Faller Douglas Vincent Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 3,082 | 1.83 | 5,640.06Derived: shares × price per share. Exact value 5640.06. | 26,286 | Direct (D) | No | F1
| Open filing 0001437749-26-023947 Read from the filing’s XML Dispute this row |
| 2026-07-17 Filed 2026-07-21 | Lindborg Stacy Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 4,907 | 1.83 | 8,979.81Derived: shares × price per share. Exact value 8979.81. | 81,629 | Direct (D) | No | F1
| Open filing 0001437749-26-023946 Read from the filing’s XML Dispute this row |
| 2026-07-17 Filed 2026-07-21 | Tardugno Michael H Director · Officer: Executive Chairman of Board | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 4,603 | 1.83 | 8,423.49Derived: shares × price per share. Exact value 8423.49. | 68,999 | Direct (D) | No | F1
| Open filing 0001437749-26-023949 Read from the filing’s XML Dispute this row |
| 2026-07-17 Filed 2026-07-21 | Eylward Susan Officer: General Counsel and Corp Sec | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,150 | 1.83 | 3,934.5Derived: shares × price per share. Exact value 3934.50. | 5,046 | Direct (D) | No | F1
| Open filing 0001437749-26-023948 Read from the filing’s XML Dispute this row |
| 2026-07-06 Filed 2026-07-07 | Eylward Susan Officer: General Counsel and Corp Sec | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 920 | 1.88 | 1,729.6Derived: shares × price per share. Exact value 1729.60. | 2,896 | Direct (D) | No | — | Open filing 0001437749-26-022944 Read from the filing’s XML Dispute this row |
| 2026-07-02 Filed 2026-07-07 | Lindborg Stacy Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,534 | 1.91 | 4,839.94Derived: shares × price per share. Exact value 4839.94. | 76,722 | Direct (D) | No | F1
| Open filing 0001437749-26-022941 Read from the filing’s XML Dispute this row |
| 2026-07-02 Filed 2026-07-07 | Faller Douglas Vincent Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 1,308 | 1.91 | 2,498.28Derived: shares × price per share. Exact value 2498.28. | 23,204 | Direct (D) | No | F1
| Open filing 0001437749-26-022943 Read from the filing’s XML Dispute this row |
| 2026-07-02 Filed 2026-07-07 | Tardugno Michael H Director · Officer: Executive Chairman of Board | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 4,410 | 1.91 | 8,423.1Derived: shares × price per share. Exact value 8423.10. | 64,396 | Direct (D) | No | F1
| Open filing 0001437749-26-022948 Read from the filing’s XML Dispute this row |
| 2026-07-02 Filed 2026-07-07 | Eylward Susan Officer: General Counsel and Corp Sec | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 920 | 1.91 | 1,757.2Derived: shares × price per share. Exact value 1757.20. | 3,816 | Direct (D) | No | F1
| Open filing 0001437749-26-022944 Read from the filing’s XML Dispute this row |
| 2026-06-29 Filed 2026-06-29 | Eylward Susan Officer: General Counsel and Corp Sec | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 11,800 | 1.752 | 20,673.6Derived: shares × price per share. Exact value 20673.600. | 2,896 | Direct (D) | No | F2
| Open filing 0001437749-26-022008 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,925 filings read, the latest filed 2026-11-19. Prior quarter ending 2026-06-30: 9,176 filings read.
Showing 1–22 of 22
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 270,497 SH | 348,941 dollars | Higher by 125,730 Prior quarter: 144,767 | Open filing 0001315863-26-000784 Filed 2026-11-16 Dispute this row |
| VANGUARD CAPITAL MANAGEMENT LLC | 46,967 SH | 60,587 dollars | Unchanged Prior quarter: 46,967 | Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row |
| GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager | 41,104 SH | 53,026 dollars | Higher by 9,475 Prior quarter: 31,629 | Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row |
| Nvest Financial, LLC | 26,286 SH | 33,909 dollars | Not in the prior quarter’s filings read | Open filing 0001951757-26-001895 Filed 2026-11-12 Dispute this row |
| STATE STREET CORP Partly reported under another manager | 15,831 SH | 20,422 dollars | Not in the prior quarter’s filings read | Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row |
| VANGUARD FIDUCIARY TRUST CO | 13,269 SH | 17,117 dollars | Unchanged Prior quarter: 13,269 | Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row |
| HRT FINANCIAL LP | 11,697 SH | 15 dollars | Not in the prior quarter’s filings read | Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row |
| NORTHERN TRUST CORP Partly reported under another manager | 10,342 SH | 13,341 dollars | Unchanged Prior quarter: 10,342 | Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row |
| Tower Research Capital LLC (TRC) Partly reported under another manager | 5,596 SH | 7,219 dollars | Higher by 1,644 Prior quarter: 3,952 | Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row |
| BlackRock, Inc. Partly reported under another manager | 4,464 SH | 5,759 dollars | Unchanged Prior quarter: 4,464 | Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row |
| WELLS FARGO COMPANY/MN Partly reported under another manager | 3,285 SH | 4,238 dollars | Lower by 57 Prior quarter: 3,342 | Open filing 0000072971-26-000342 Filed 2026-11-16 Dispute this row |
| UBS Group AG Partly reported under another manager | 2,027 SH | 2,615 dollars | Lower by 3,176 Prior quarter: 5,203 | Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row |
| MORGAN STANLEY Partly reported under another manager | 1,503 SH | 1,940 dollars | Lower by 71 Prior quarter: 1,574 | Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row |
| SBI Securities Co., Ltd. | 1,027 SH | 1,325 dollars | Unchanged Prior quarter: 1,027 | Open filing 0001851815-26-000004 Filed 2026-10-22 Dispute this row |
| CITIGROUP INC Partly reported under another manager | 922 SH | 1,189 dollars | Not in the prior quarter’s filings read | Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row |
| GROUP ONE TRADING LLC | 6 SH | 8 dollars | Unchanged Prior quarter: 6 | Open filing 0000932540-26-000017 Filed 2026-11-10 Dispute this row |
| OSAIC HOLDINGS, INC. Partly reported under another manager | 3 SH | 3 dollars | Higher by 1 Prior quarter: 2 | Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 2 SH | 3 dollars | Lower by 1 Prior quarter: 3 | Open filing 0001085146-26-000940 Filed 2026-11-13 Dispute this row |
| Steigerwald, Gordon Koch Inc. | 1 SH | 1 dollars | Unchanged Prior quarter: 1 | Open filing 0001731876-26-000009 Filed 2026-11-12 Dispute this row |
| GK Wealth Management LLC | 1 SH | 1 dollars | Not in the prior quarter’s filings read | Open filing 0002069222-26-000005 Filed 2026-10-09 Dispute this row |
| ROYAL BANK OF CANADA Partly reported under another manager | 1 SH | 0 dollars | Unchanged Prior quarter: 1 | Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row |
| Game Plan Financial Advisors, LLC | 1 SH | 1 dollars | Unchanged Prior quarter: 1 | Open filing 0001802952-26-000004 Filed 2026-11-10 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- Riverview Capital Advisers, LLC 34,364 SH
- Virtu Financial LLC 17,456 SH
- BARCLAYS PLC 194 SH
- JPMORGAN CHASE CO 134 SH
- Caitong International Asset Management Co., Ltd 8 SH
- MERCER GLOBAL ADVISORS INC /ADV 1 SH
- FMR LLC 1 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
Showing 1–4 of 4
| Member | Transaction date | Type | Amount | Owner | Report |
|---|---|---|---|---|---|
| Hon. Roger W. Marshall (KS01) | 2017-06-05 | Purchase | $1,001 - $15,000 | DC | 2018-08-06 |
| Hon. Roger W. Marshall (KS01) | 2017-06-05 | Sale | $1,001 - $15,000 | DC | 2018-08-06 |
| Hon. Roger W. Marshall (KS01) | 2017-06-16 | Purchase | $1,001 - $15,000 | DC | 2018-08-06 |
| Hon. Roger W. Marshall (KS01) | 2017-06-16 | Sale | $1,001 - $15,000 | DC | 2018-08-06 |
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| Armistice Capital, LLC Common stock, par value $0.01 per share | 4.99 | 280,508.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 3 | Open filing 0001172661-26-005233 Dispute this row |
| Steven Boyd Common stock, par value $0.01 per share | 4.99 | 280,508.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 3 | Open filing 0001172661-26-005233 Dispute this row |
| Armistice Capital, LLC Common stock, par value $0.01 per share | 9.99 | 450,315.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001172661-26-003591 Dispute this row |
| Steven Boyd Common stock, par value $0.01 per share | 9.99 | 450,315.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001172661-26-003591 Dispute this row |
| Armistice Capital, LLC Common stock, par value $0.01 per share | 9.99 | 396,718.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0001172661-26-002157 Dispute this row |
| Steven Boyd Common stock, par value $0.01 per share | 9.99 | 396,718.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0001172661-26-002157 Dispute this row |
| Armistice Capital, LLC Common stock, par value $0.01 per share | 9.99 | 349,917.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G | Open filing 0001172661-26-001255 Dispute this row |
| Steven Boyd Common stock, par value $0.01 per share | 9.99 | 349,917.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G | Open filing 0001172661-26-001255 Dispute this row |
| Ayrton Capital LLC Common stock, par value $0.01 per share | 0.0 | 2,000.00 | 06/30/2025 Filed 2025-08-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001641172-25-023310 Dispute this row |
| Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B Common stock, par value $0.01 per share | 0.0 | 2,000.00 | 06/30/2025 Filed 2025-08-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001641172-25-023310 Dispute this row |
| Waqas Khatri Common stock, par value $0.01 per share | 0.0 | 2,000.00 | 06/30/2025 Filed 2025-08-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001641172-25-023310 Dispute this row |
| Mitchell P. Kopin Common stock, par value $0.01 per share | 4.99 | 1,067,196.00 | 06/30/2025 Filed 2025-08-12 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-25-075077 Dispute this row |
| Daniel B. Asher Common stock, par value $0.01 per share | 4.99 | 1,067,196.00 | 06/30/2025 Filed 2025-08-12 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-25-075077 Dispute this row |
| Intracoastal Capital LLC Common stock, par value $0.01 per share | 4.99 | 1,067,196.00 | 06/30/2025 Filed 2025-08-12 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-25-075077 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,592,621 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 17,857 |
| 2016 | 222,642 |
| 2017 | 222,009 |
| 2018 | 223,345 |
| 2019 | 216,482 |
| 2020 | 218,850 |
| 2021 | 249,835 |
| 2022 | 231,682 |
| 2023 | 229,674 |
| 2024 | 234,045 |
| 2025 | 235,520 |
| 2026 | 262,467 |
Filings made before the SEC required XML are listed, not extracted.